US-based healthcare company Eli Lilly and Company has agreed to acquire AurKa Pharma Inc.
Eli Lilly will purchase all shares of AurKa Pharma, Inc, as part of the transaction. The shareholders of AurKa Pharma will get an upfront payment of $110m from Eli Lilly, as part of the transaction.
AurKa Pharma shareholders will get up to $465m in regulatory and sales milestones, upon approval of the aurora kinase A inhibitor AK-01 in the US and other markets.
Based in Canada, the target company is involved in the development of medication for cancer treatment. It was established by TVM Capital Life Science.
Fujifilm Holdings Corp has agreed to purchase 34% additional share in Toyama Chemical Co Ltd from Taisho Pharmaceutical Holdings Co Ltd.
Toyama Chemical will become a wholly owned subsidiary of Fujifilm Holdings upon completion of the acquisition.
Fujifilm plans to merge Toyama Chemical and Fujifilm RI Pharma Co Ltd in order to establish a combined entity named Fujifilm Toyama Chemical Co Ltd by October 2018.
Toyama Chemical Co Ltd and Taisho Pharmaceutical Holdings Co Ltd are pharmaceutical companies based in Japan.
The new entity will focus on accelerating the development of new diagnostic and therapeutic drugs.
Canopy Growth Corporation (formerly Tweed Marijuana Inc) has agreed to purchase the remaining 33% share of BC Tweed Joint Venture Inc.
Canopy Growth will issue C$374m ($292.09m) worth common shares on the volume-weighted average price (VWAP), as well as pay C$1m ($780,000) in cash.
The company will also issue C$20m ($15.62m) worth common shares with an option to purchase certain future infrastructure from the operators.
The minority shareholders of BC Tweed will manage the operations of BC Tweed Joint Venture for a period of five years.
Canopy Growth is a diversified cannabis and hemp company, while BC Tweed Joint Venture is a developer and marketer of pharmaceutical products.
Both companies are based in Canada.
Switzerland-based Novartis has acquired AveXis for $8.7bn.
Based in the US, AveXis is a clinical-stage gene therapy company, which will become a wholly owned subsidiary of Novartis upon completion of the acquisition.
The acquisition will expand Novartis’ existing global footprint in neuroscience and provide solutions for life-threatening neurological genetic diseases with the support of AveXis’s gene delivery platform.